Increased local DNA methylation disorder in AMLs with DNMT3A-destabilizing variants and its clinical implication

Area of Science:

• Genetics
• Epigenetics
• Cancer Biology

Background:

• The role of de novo methyltransferase DNMT3A mutations in acute myeloid leukemia (AML) is complex and not fully understood.
• DNMT3A mutations are common in AML, influencing disease pathology.
• DNMT3A-destabilizing mutations (DNMT3A^INS) have recently emerged as significant in AML.

Purpose of the Study:

• To investigate the common characteristics of DNMT3A^INS AML methylomes.
• To compare DNMT3A^INS AML methylomes with DNMT3A^R882 AML methylomes.
• To elucidate the mechanistic link between DNMT3A mutations and AML pathology.

Main Methods:

• Computational analyses of methylomes from DNMT3A^INS AML patients.
• Comparative analysis of methylation patterns between DNMT3A^INS and DNMT3A^R882 AML subtypes.
• Association studies linking epigenetic heterogeneity to transcriptional variability and treatment response.

Main Results:

• DNMT3A^INS AML methylomes show increased intratumor DNA methylation heterogeneity compared to DNMT3A^R882 AML.
• This heterogeneity is concentrated in bivalent chromatin domains.
• Epigenetic heterogeneity correlates with transcriptional variability of developmental and membrane-associated factors and predicts response to hypomethylating agents.

Conclusions:

• Aberrant epigenomic heterogeneity in AML originates from genomic alterations in DNMT3A.
• Stochastic DNA methylations at bivalent domains are crucial for AML cell survival.
• This study proposes a novel mechanistic model for disease-associated epigenomic heterogeneity.